(4S)-4-[[3-[2-(Methylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone
CAS: 139264-35-0
Ref. 3D-FM75153
1mg | Descontinuado | ||
2mg | Descontinuado | ||
5mg | Descontinuado | ||
10mg | Descontinuado | ||
25mg | Descontinuado |
Informação sobre produto
- (4S)-4-({3-[2-(methylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
- 183C91
- 2-Oxazolidinone, 4-[[3-[2-(methylamino)ethyl]-1H-indol-5-yl]methyl]-, (4S)-
- 2-Oxazolidinone, 4-[[3-[2-(methylamino)ethyl]-1H-indol-5-yl]methyl]-, (S)-
- 4-({3-[2-(methylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
- 4-[[3-[2-(Methylamino)ethyl]-1H-indol-5-yl]methyl-2-oxazolidinon
- 4-[[3-[2-(Methylamino)ethyl]-1H-indol-5-yl]methyl-2-oxazolidinone
- N-Desmethyl Zolmitriptan
Rizatriptan is a selective serotonin receptor agonist that is used to treat and prevent migraine attacks. Rizatriptan binds to the 5-HT1B/1D receptors, which are located in cranial blood vessels, and causes vasoconstriction. This medication can be administered nasally or orally. A pharmacokinetic study has been performed using an analytical method of mass spectrometric with matrix effect and bioequivalence studies using a Hplc-MS/MS method. The bioanalytical method used was an LC-MS/MS method with a UV detector.